share_log

Piper Sandler Initiates Coverage On Orchestra BioMed Hldgs With Overweight Rating, Announces Price Target of $15

Piper Sandler Initiates Coverage On Orchestra BioMed Hldgs With Overweight Rating, Announces Price Target of $15

派珀·桑德勒以增持评级开始对管弦乐团BioMed Hldgs进行报道,宣布目标股价为15美元
Benzinga ·  2023/02/24 08:53

Piper Sandler analyst Matt O'Brien initiates coverage on Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight rating and announces Price Target of $15.

Piper Sandler分析师马特·奥布莱恩对乐团BioMed Hldgs(纳斯达克:OBIO)进行了增持评级,并宣布目标价为15美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发